Pfeiffenberger Brent 4

4 · Century Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 5, 2026

Century Therapeutics (IPSC) CEO Brent Pfeiffenberger Receives Award

What Happened

Brent Pfeiffenberger, President, CEO and a director of Century Therapeutics (IPSC), received compensation awards on Feb 2, 2026 consisting of 475,000 restricted stock units (RSUs) and 945,000 derivative/option-style awards. Both awards were granted at $0.00 per share (i.e., they are compensation grants, not purchases), and the filing records $0 cash paid.

Key Details

Transaction date and price: 2026-02-02, granted at $0.00 per share (award/grant)
Total instruments granted: 475,000 RSUs + 945,000 derivative awards = 1,420,000 total
Vesting / settlement:
- RSUs (475,000): vest 25% on Feb 2, 2027, then the remaining 75% vest quarterly over the following three years; RSUs will be settled in common shares at each vesting date (Footnote F1).
- Option-style award (945,000): vests 25% on Feb 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter (Footnote F2).
Shares owned after transaction: not disclosed in the Form 4 filing
Filing timeliness: reported on Form 4 filed Feb 4, 2026 for a Feb 2, 2026 grant — appears timely under the two-business-day requirement
No sales, exercises, or tax-withholding transactions were reported in this filing

Context

These grants are standard equity compensation for executives and are subject to service-based vesting; they do not represent an immediate purchase of publicly traded shares. RSUs convert to actual shares only when they vest; option-style awards must vest before they can be exercised. Such awards can dilute shareholders when settled, but they are a routine part of executive pay and do not by themselves indicate buying or selling sentiment.

Form 4

Period: 2026-02-02

DirectorPresident and CEO

Transactions

Award
Common Stock
[F1]
2026-02-02+475,000→ 3,797,990 total
Award
Stock Option (right to buy)
[F2]
2026-02-02+945,000→ 945,000 total
Exercise: $1.84Exp: 2036-02-02→ Common Stock (945,000 underlying)

Footnotes (2)

[F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
[F2]The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

Signature

/s/ Douglas Carr, Attorney-in-Fact|2026-02-04

1 file